Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interstitial brachytherapy procedures for brain tumors

P K Sneed1, M W McDermott, P H Gutin

  • 1Department of Radiation Oncology, University of California, San Francisco 94143-0226, USA.

Seminars in Surgical Oncology
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative MR Imaging to Differentiate Chordoid Meningiomas from Other Meningioma Histologic Subtypes.

AJNR. American journal of neuroradiology·2019
Same author

Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI.

Clinical radiology·2015
Same author

Delayed neurological deficit following resection of tuberculum sellae meningioma: report of two cases, one with permanent and one with reversible visual impairment.

Acta neurochirurgica·2014
Same author

Recurrent syncope due to refractory cerebral venous sinus thrombosis and transient elevations of intracranial pressure.

The Neurohospitalist·2014
Same author

Super-resolution track density imaging of glioblastoma: histopathologic correlation.

AJNR. American journal of neuroradiology·2013
Same author

A two-step optimization method for improving multiple brain lesion treatments with robotic radiosurgery.

Technology in cancer research & treatment·2011

Brachytherapy shows promise for brain tumors, offering high survival rates for low-grade gliomas and improved survival for high-grade gliomas. Ongoing research aims to enhance tumor control while minimizing radiation side effects.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Neurosurgery

Background:

  • Brachytherapy is an established treatment modality for various brain tumors.
  • Different dose rates and total doses are employed based on glioma grade.
  • Previous studies indicate significant survival benefits for both low- and high-grade gliomas.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of brachytherapy in treating brain tumors.
  • To analyze survival outcomes for different glioma grades treated with brachytherapy.
  • To identify challenges and future directions for optimizing brachytherapy in malignant glioma treatment.

Main Methods:

  • Review of clinical data and outcomes for patients treated with brachytherapy.
  • Analysis of survival probabilities and complication rates (e.g., radiation necrosis).

Related Experiment Videos

  • Comparison of outcomes for low-grade versus high-grade gliomas.

    • Main Results:

    • Very low-dose rate brachytherapy for low-grade gliomas yielded 5- and 10-year survival rates of 85% and 83% (pilocytic astrocytomas) and 61% and 51% (grade II astrocytomas), with low rates of radiation necrosis (2.6%).
    • Temporary implants for high-grade gliomas resulted in median survival times of 12-13 months for recurrent cases and 18-19 months for primary glioblastomas (with external beam radiotherapy boost).
    • A randomized trial confirmed improved survival for high-grade glioma patients receiving a brachytherapy boost, though over 50% required reoperation for progression or necrosis.

    Conclusions:

    • Brachytherapy is an effective treatment for brain tumors, offering favorable survival outcomes for low-grade gliomas and improved survival when used as a boost for high-grade gliomas.
    • While effective, brachytherapy for malignant gliomas is associated with a significant risk of reoperation due to tumor progression or radiation necrosis.
    • Further research is necessary to develop strategies that enhance local tumor control and reduce radiation-induced toxicity.